venBio Global Strategic Fund III, L.P.

venBio Global Strategic Fund III, L.P. discloses dealings in 4 companies, chiefly Artiva Biotherapeutics, Inc., Elevation Oncology, Inc. and RayzeBio, Inc. Over a trading history stretching from 29 June 2021 to 22 July 2024, the count stands at 12 filings.

Market trades split into 3 purchases (€17.3M) and 1 sale (€2.7M). On balance, insiders were net buyers of €14.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2024: 1 purchase and no sales on the market.

Half of the purchases are above €4.6M and half below. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 22 July 2024: a transaction, in Artiva Biotherapeutics, Inc. The last purchase on record was published on 22 July 2024, which is 824 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.